Premenstrual Syndrome Treatment Market Size to Reach US$ 1,683 Million By 2028

According to the latest report by IMARC Group, titled "Premenstrual Syndrome Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028," The global premenstrual syndrome treatment market size reached US$ 1,346 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,683 Million by 2028, exhibiting a growth rate (CAGR) of 3.9% during 2023-2028.

Premenstrual syndrome (PMS) treatment represents the therapeutic process utilized for minimizing physical, emotional, and psychological symptoms, such as breast tenderness, body pain, bloating, fatigue, mood fluctuations, and anxiety, in women. It generally involves the use of analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants, diuretics, ovarian suppression agents, hormonal contraceptives, etc. They are commonly available over the counter (OTC) or are prescribed by a doctor. As such, novel PMS treatment drugs, including creams, topical gels, capsules, and suppositories, are manufactured by using extracts for the management of mood imbalances, facilitating muscle relaxation, minimizing uterine cramps, etc.

Request Free Sample Report: https://www.imarcgroup.com/premenstrual-syndrome-treatment-market/requestsample

Premenstrual Syndrome Treatment Market Trends and Drivers:

The growing prevalence of PMS and premenstrual dysphoric disorder (PMDD), owing to the sedentary lifestyles and hectic schedules of the female working population, is primarily driving the premenstrual syndrome treatment market. Additionally, the rising consumer awareness towards available treatment alternatives for PMS and other related disorders is further catalyzing the market growth. Besides this, leading manufacturers are developing medications that have minimal side effects and help in maintaining the appropriate pH balance in the body, which is acting as another significant growth-inducing factor. Moreover, the widespread adoption of nutritional supplements that are produced by using plant-based sources to provide relief from PMS is positively influencing the global market. Apart from this, these supplements contain the recommended amount of nutrients, such as magnesium, calcium, potassium, proteins, etc., that assist in reducing fatigue and easing anxiety and depression. Furthermore, the development of smartphone applications by healthcare organizations that periodically record emotional and physiological changes occurring in the body and send notification alerts as medication reminders is expected to fuel the premenstrual syndrome treatment market over the forecasted period.

Premenstrual Syndrome Treatment Market 2023-2028 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

AbbVie Inc.
BASF SE
Bayer AG
Reddy's Laboratories Ltd
Eli Lilly and Company.
GlaxoSmithKline Plc.
Lundbeck A/S
Pfizer Inc.
SHIONOGI & Co. Ltd.

The report has segmented the market on the basis on region, drug type, type, distribution channel.

Breakup by Drug Type:
Analgesics
Antidepressants
Oral Contraceptives and Ovarian Suppression Agents
Others

Breakup by Type:
Prescription
Prescription

Breakup by Distribution Channel:
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Stores

Breakup by Region:
North America
Asia-Pacific
Europe
Latin America
Middle East and Africa

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/premenstrual-syndrome-treatment-market

Key highlights of the report:

Market Performance (2017-2022)
Market Outlook (2023-2028)
Porter's Five Forces Analysis
Market Drivers and Success Factors
SWOT Analysis
Value Chain
Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Browse Top Trending Reports:

https://www.openpr.com/news/3011738/apple-juice-market-2023-2028-share-size-growth-top

https://www.openpr.com/news/3011761/europe-cement-market-report-2023-2028-size-share-industry

https://www.openpr.com/news/3011840/india-cement-market-2023-size-scope-growth-price-trends

https://www.openpr.com/news/3011882/mobile-gaming-market-2023-2028-share-size-growth-top

https://www.openpr.com/news/3011903/factoring-market-size-to-hit-us-5-179-3-billion-by-2028-cagr

https://www.openpr.com/news/3011942/crowdfunding-market-size-to-hit-us-28-9-billion-by-2028-cagr

https://www.openpr.com/news/3011977/digital-map-market-2023-2028-share-size-growth-top

Contact Us:

IMARC Group
Email: sales@imarcgroup.com
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Website: https://www.imarcgroup.com/
Follow us on Twitter: @imarcglobal
Linkedin: https://www.linkedin.com/company/imarc-group

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

This release was published on openPR.